Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd is in the business of TPP and its allied products[1]
- Market Cap ₹ 45.6 Cr.
- Current Price ₹ 58.0
- High / Low ₹ 115 / 47.3
- Stock P/E 22.0
- Book Value ₹ 20.8
- Dividend Yield 0.00 %
- ROCE 13.0 %
- ROE 9.79 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 63.0 to 43.3 days.
Cons
- Stock is trading at 2.79 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 9.51% over last 3 years.
- Earnings include an other income of Rs.1.87 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
32 | 29 | 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 113 | |
30 | 29 | 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 108 | |
Operating Profit | 2 | -0 | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 5 | 5 |
OPM % | 5% | -1% | 7% | -3% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 4% |
0 | 0 | -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | |
Interest | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 0 | -2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
Tax % | 43% | 3% | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | |
0 | -2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | |
EPS in Rs | 0.23 | -2.56 | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.63 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 18% |
3 Years: | 35% |
TTM: | 71% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 20% |
3 Years: | 26% |
TTM: | 60% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 38% |
3 Years: | 18% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 8% |
3 Years: | 10% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 3 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 8 |
6 | 8 | 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 27 | |
6 | 7 | 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 33 | |
Total Liabilities | 23 | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 77 |
7 | 8 | 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | |
CWIP | 1 | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
15 | 16 | 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | |
Total Assets | 23 | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 77 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 1 | 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | -3 | |
-1 | -0 | -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | |
1 | -0 | -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | 3 | |
Net Cash Flow | -1 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 81 | 88 | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 |
Inventory Days | 86 | 94 | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 |
Days Payable | 93 | 118 | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 |
Cash Conversion Cycle | 74 | 65 | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 |
Working Capital Days | 79 | 77 | 87 | 103 | 157 | 307 | 157 | 168 | 173 | 94 | 81 | 116 |
ROCE % | 7% | -4% | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 13% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - Confirmation of dematerialization and cancellation of securities.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
3 Apr - Confirmation of not being a Large Corporate entity.
- Closure of Trading Window 24 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Feb - Publication of Unaudited Financial Results for the Third Quarter and Nine months ended 31st December, 2024 as per SEBI (LODR) Regulations, 2015.
-
Integrated Filing (Financial)
14 Feb - Integrated financial results for Q3 and nine months ended December 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2][3][4]
RIL manufactures Bulk Drugs, Drug Intermediates, Nutraceuticals, and fine chemicals. It produces Active Pharmaceutical Ingredients such as Fluconazole, Sildenafil Citrate, Losartan Potassium and Triphenyl Phosphine (which goes into production of Cephalosporins, Statins etc.,) and Nutraceuticals such as Glucosamine salts.
Its products are used in chemical and pharmaceutical industry and supplied globally